Last updated on September 2018

Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629)

Brief description of study

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.

Clinical Study Identifier: NCT03284424

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Royal Brisbane and Women s Hospital ( Site 0407)
Herston, Australia
  Connect »

Study Coordinator

Princess Alexandra Hospital ( Site 0405)
Brisbane, Australia
  Connect »